Eine Studie zu Atezolizumab bei lokal fortgeschrittenem oder metastasierendem urothelialem oder nicht-urothelialem Karzinom der Harnwege

A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

  • Krebs
Bitte beachten Sie, dass der Rekrutierungsstatus der Studie an Ihrem Standort vom Gesamtstatus der Studie abweichen kann, da einige Studienzentren früher rekrutieren als andere.
Status der Studie:

Abgeschlossen

Diese Studie läuft in
Städte
  • Dresden
  • Erlangen
  • Göttingen
  • Halle (Saale)
  • Hannover
  • Heidelberg
  • Lübeck
  • Mönchengladbach
  • München
  • Münster
  • Tübingen
  • Ulm
Studien-ID:

NCT02928406 2016-002625-11 MO29983

      Studienzentren finden

      Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden für Laien bearbeitet.

      Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden nicht geändert.

      Results Disclaimer

      Studienzusammenfassung

      This Phase IIIb, multicenter study will assess the safety of atezolizumab as second- to fourth-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in addition to evaluate the efficacy of atezolizumab and potential tumor biomarkers associated with atezolizumab.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT02928406, MO29983, 2016-002625-11 Studien-ID
      Atezolizumab Treatments
      Urinary Tract Cancer Condition
      Official Title

      An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

      Einschlusskriterien

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participants with histologically documented locally advanced (tumor [T] 4b, any node [N]; or any T, N 2-3) or metastatic (M1, Stage IV) urothelial or non-urothelial carcinoma of the urinary tract
      • Participants with measurable and/or non-measurable disease according to RECIST v1.1
      • Participants must have progressed during or following treatment with at least one prior (and not more than 3) treatments for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
      • If available, a representative formalin-fixed paraffin-embedded (FFPE) tumor specimen block should be submitted
      • Eastern cooperative oncology group (ECOG) performance status 0, 1 or 2
      Exclusion Criteria
      • Treatment with more than three prior lines of systemic therapy for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
      • Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to study treatment initiation
      • Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were not on active drug in that prior trial are eligible
      • Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were in the follow-up phase of that prior trial and had stopped receiving active drug 4 or more weeks before study treatment initiation are eligible
      • Malignancies other than the one studied in this protocol within 5 years prior to Cycle 1, Day 1
      • Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol
      • Significant renal disorder indicating a need for renal transplant

      Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de

       

      Über klinische Studien

      Erfahren Sie mehr über klinische Studien und wie sie durchgeführt werden

      Erfahren Sie mehr